1038P A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: preliminary analysis for first-line (1L) treatment of non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN).

Authors :: Riess, J.W.
Cohen, E.
Spicer, J.
Shaw, P.H.
Rubio Perez, J.
Medina Rodríguez, L.
Chaney, M.F.
O'Neill, S.
Pedersen, A.W.
McDowell, D.
Ehrnrooth, E.
Garrido Lopez, P.
Source :: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS630-S630. 1p.
Publication Year :: 2023

Subjects :: *NON-small-cell lung carcinoma
*SQUAMOUS cell carcinoma
*VACCINE trials
*NECK
*PEMBROLIZUMAB

Full Text Access

Tools